Fellowship to Identify New Mechanisms of Tamoxifen Resistance in Breast Cancer Patients
Final rept. 15 Sep 1994-14 Apr 1999
TEXAS UNIV HEALTH SCIENCE CENTER AT SANANTONIO
Pagination or Media Count:
The non-steroidal antiestrogen tamoxifen TAM has been used successfully in the treatment of tens of thousands of women with breast cancer, and has been shown to increase both disease-free and overall survival in treated patients. Unfortunately, virtually all patients treated with TAM eventually develop resistant disease. The research funded by this fellowship was directed at increasing our understanding of the mechanisms leading to the development of tamoxifen resistance. The two Specific Aims of this proposal have been completed and three altered estrogen receptors ERs have been identified from clinical samples, one of which exhibits a hormone-independent phenotype in transient assays Aim 1 and 2. This work represents the work of the first postdoctoral fellow to work on the project, Dr. Douglas Wolf. We have also worked out the technical aspects of microdissection of archival and frozen clinical tumor samples to improve the use of differential display technologies to examine these samples for altered gene expression coincident with the phenotype of tamoxifen resistance Aims 3 and 4. Dr. Wolf left the laboratory after completion of Aim 3, and Aim 4 of the fellowship project was completed by Dr. Rhonda Hansen.
- Medicine and Medical Research